QUIBIM Precision Prostate (qp-Prostate)

by QUIBIM S.L.  · Based in Spain → — Your AI solution for advanced prostate cancer detection.
Oncology Radiology Urology
Website
Claim this tool
Is this the maker? Claim the company →

Contact vendor
Regulatory Status Disclosed

Overview

QP-Prostate (QUIBIM Precision Prostate) is an AI-powered medical imaging software designed to revolutionize prostate MRI interpretation and enhance diagnostic accuracy for healthcare professionals. It leverages advanced artificial intelligence and image processing techniques to provide state-of-the-art analysis of prostate MRI scans. The tool is compatible with standard workstations and facilitates the visualization and analysis of DICOM data.

Key functionalities include automated segmentation of critical prostate regions, such as the peripheral zone, transitional and central zone, and seminal vesicles, with high accuracy. It also incorporates AI-QUAL™ for automated assessment of prostate MRI image quality based on PI-QUAL v2 guidelines, ensuring radiologists work with high-quality images. QP-Prostate’s AI algorithm identifies and stratifies aggressive prostate cancer lesions by likelihood, providing confidence-based classification scores. It supports PI-RADS compliant structured reporting, streamlines workflows by automating tasks, and aids in fusion biopsy and focal therapy planning. The solution is designed for seamless integration into existing PACS and electronic health record systems, delivering precise, quantitative information and automating tasks to improve and standardize decision-making in prostate cancer care.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • AI algorithm for detection and stratification of aggressive prostate cancer lesions
  • Automated prostate segmentation (peripheral zone, transitional/central zone, seminal vesicles)
  • AI-QUALu2122 for automated prostate MRI image quality assessment (PI-QUAL v2 guidelines)
  • PI-RADS compliant structured reporting
  • Support for fusion biopsy planning
  • Support for focal therapy planning
  • Seamless integration with PACS and fusion biopsy systems
  • Automated diffusion and perfusion analysis (ADC map, synthesized b-1400s/mm2)
  • Advanced 3D visualization and editing tools
  • Risk stratification for clinically significant prostate cancer (High/Moderate risk levels)

Use Cases

  • Early detection of prostate cancer
  • Improving diagnostic accuracy for radiologists
  • Streamlining radiology workflows and reducing interpretation time
  • Assisting in fusion biopsy planning and guidance
  • Supporting focal therapy planning
  • Enhancing patient management and follow-up in prostate cancer care

What Physicians Need to Know

Key Capabilities
QP-Prostate offers automated prostate segmentation with 88% accuracy, lesion detection and risk stratification (High and Moderate) for clinically significant prostate cancer, and automated assessment of prostate MRI image quality based on PI-QUAL v2 guidelines. It also provides quantitative information such as prostate volume, dimensions, Apparent Diffusion Coefficient (ADC) map, computed high b-value, and perfusion metrics (K trans, K ep, V e). The software supports PI-RADS v2.1 guidelines compliance and offers 3D visualization of the prostate gland and lesions.
Clinical Utility
The tool aims to increase diagnostic accuracy and early detection of prostate cancer, streamline radiologists' workflows by automating tasks like segmentation and reporting, and pre-populate radiology reports. It helps in fusion biopsy planning and can reduce interpretation time. QP-Prostate has been shown to increase expert radiologists' detection rates by up to 90% and improve radiologist sensitivity by up to 10%.
Integration Options
QP-Prostate seamlessly integrates with local PACS systems, allowing for automatic analysis and storage of results directly within patient folders. It is also fully integrated into most fusion biopsy devices.
Compliance Status
QP-Prostate has received CE mark for the European Union (Class IIb device under MDR regulation), UKCA mark for the United Kingdom, and FDA 510(k) clearance in the U.S. as a CADe/CADx device. It is also approved by the TGA in Australia and has received a Health Canada Licence.
Pricing Model
The pricing model is subscription-based, determined by the number of analyses performed.
User Experience
The software is designed to streamline workflows, enhance user convenience, and reduce administrative burden. It features an upgraded user interface with guaranteed access to original images, editing tools, and flexible overlays for AI-generated findings, ensuring clinicians maintain full autonomy.
Support Quality
Quibim provides a Support Center Hub with resources such as installation guides, quick user guides, and Instructions For Use (IFU) documents for QP-Prostate and its various components.
Evidence Base
QP-Prostate's algorithms are trained with post-biopsy pathology data as ground truth. A validated international study showed the software efficiently segments imagery of the prostate gland with 88% accuracy. Clinical validation studies, including a multi-reader, multi-case study, demonstrated superior aided radiological performance versus unaided interpretation and met the primary endpoint of area under the receiving operating curve (AUROC) using biopsy as ground truth.
Physician Tip

QP-Prostate is an image processing software package intended for use by trained professionals, including radiologists specializing in prostate imaging, urologists, and oncologists. It is crucial to remember that patient management decisions should not be based solely on the results of QP-Prostate, as it does not perform a diagnostic function but aids in visualization and analysis of DICOM data. The tool can significantly enhance diagnostic accuracy and efficiency, especially in adhering to PI-RADS v2.1 guidelines and identifying aggressive cancer lesions.

QP-Prostate is designed for seamless integration with existing PACS systems, automating analyses and storing results directly in patient folders. It also integrates with fusion biopsy devices to support more accurate targeted biopsies. Philips offers an integrated solution with DynaCAD Prostate, bringing QP-Prostate's AI capabilities directly into the DynaCAD workflow for a unified experience.

Details

Category Oncology AI
Pricing Contact vendor
DeploymentOn-premise (standard workstation compatible) and cloud-integrated for large health systems.
Compliance
BAA Available Yes AI-estimated
HIPAA Compliant Yes AI-estimated
FDA Status Cleared AI-estimated
Integrations
EHR Not specified
Specialties Oncology, Radiology, Urology

What the Web Says

QUIBIM Precision Prostate (qp-Prostate) is an AI-assisted software designed to enhance the detection and diagnosis of prostate cancer by analyzing prostate MRI images. It provides automated segmentation, AI-driven lesion detection, and PI-RADS compliant reporting, aiming to improve diagnostic accuracy and aid in treatment planning. The tool is intended for use by trained professionals and is not meant to be solely relied upon for diagnostic decisions.

Overall: Positive

Strengths

  • Enhances detection and diagnosis of prostate cancer through AI-assisted analysis of MRI images.
  • Offers automated prostate segmentation (peripheral zone, transitional/central zone, seminal vesicles).
  • Provides AI-driven lesion detection and stratification of aggressive prostate cancer.
  • Generates PI-RADS compliant structured reporting.
  • Supports fusion and focal therapy planning.
  • Offers flexible deployment options, including on-premise and cloud-integrated solutions.

Limitations

  • Not intended for sole reliance in diagnostic decisions; professional review is required.
  • No specific negative reviews or opinions were found on platforms like Reddit, G2, or Capterra.

Based on reviews from: nih.gov, warrick.net, parikhradiology.com, thno.org, physicianaitools.com

Last updated: 2026-10-31

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate QUIBIM Precision Prostate (qp-Prostate)

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

quibim.ai
QP-Prostate® Receives Health Canada Licence, Expanding Quibim's Reach to Canada
Quibim's AI-powered solution for prostate MRI analysis, QP-Prostate®, has received a Medical Device Licence from Health Canada, clearing it for use across Canada where prostate cancer is the most commonly diagnosed cancer among men. This expands Quibim's global reach, adding Canada to a list of markets including the EU, US, UK, Switzerland, Chile, Mexico, Argentina, Brazil, and Australia where QP-Prostate® is already cleared for clinical use.
2026-06
quibim.ai
New enhancements deliver advanced 3D visualization capabilities and an end-to-end prostate cancer management solution.
Quibim announced the launch of its next-generation oncology ecosystem platform at the Radiological Society of North America (RSNA) 2025 Annual Meeting, positioning QP-Prostate® as a comprehensive, end-to-end management workflow for prostate cancer care. This major product update includes an upgraded user interface with advanced 3D visualization and editing tools, and an enhanced structured report compliant with PI-RADS v2.1.
2025-11
quibim.ai
Quibim's AI Tool for Prostate Cancer Detection Selected for NHS Rollout Across Seven UK Hospitals
Quibim's flagship solution, QP-Prostate, has been selected for a major NHS-backed rollout across seven hospitals in England, aiming to improve early detection of prostate cancer. The two-year project will evaluate diagnostic accuracy, cost-effectiveness, and health equity impact, with early clinical data suggesting QP-Prostate can help detect 10.6% more early-stage prostate cancers.
2025-07
quibim.ai
AI-QUAL™: Automated Prostate Image Quality Assessment
Quibim launched AI-QUAL™, a new feature for its QP-Prostate® platform that automates the assessment of prostate MRI image quality based on PI-QUAL v2 guidelines. This innovation aims to standardize prostate MRI quality, enhance diagnostic confidence, and streamline radiology workflows by automatically detecting common artifacts and assigning a standardized quality score.
2025-06
quibim.ai
Quibim's QP-Prostate® CAD, including lesion detection and diagnosis capability, cleared by FDA
Quibim announced that the prostate cancer lesion detection capability of its flagship QP-Prostate® CAD solution has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). This clearance marks a significant milestone in Quibim's mission to enhance prostate cancer detection and treatment, following its successful implementation in the EU, UK, and Australia.
2025-03
quibim.ai
Quibim adds industry-leading cancer detection capability to its prostate tool based on AI, QP-Prostate
Quibim has added an industry-leading cancer detection capability to its AI-powered prostate tool, QP-Prostate, which uses algorithms trained on actual pathology data as ground truth. The updated product has received CE and UKCA marks, allowing clinicians in the EU and UK to use it for AI-driven lesion detection.
2024-01
quibim.ai
Quibim scores CE mark and UKCA certification for QP-Prostate®
Quibim achieved MDR (class IIb) and UKCA certifications for QP-Prostate®, allowing its commercialization in European and British markets. This makes QP-Prostate® one of the first AI products cleared under the new and demanding MDR regulation, building on its prior FDA 510(k) clearance in 2021.
2022-10
prnewswire.com
Quibim Launches QP-Prostate, an AI-based MR Solution for Prostate Cancer Detection, After Receiving FDA 510(k) Clearance
Quibim announced the launch of qp-Prostate, an AI-based Magnetic Resonance (MR) solution for prostate cancer, after receiving 510(k) clearance by the US Food and Drug Administration. The solution aims to increase diagnostic accuracy and early prostate cancer detection by aiding in prostate MRI reporting from visualization to quantification.
2021-03

Videos

Product demos, reviews, and walkthroughs for QUIBIM Precision Prostate (qp-Prostate).

View all on YouTube

Frequently Asked Questions

QUIBIM Precision Prostate (qp-Prostate) is an AI-powered medical imaging software designed to support radiologists in detecting clinically significant prostate cancer. It automates tasks like prostate segmentation, lesion detection, and risk scoring (High and Moderate) for the presence of csPCa. The software also provides quantitative information such as prostate volume and dimensions, Apparent Diffusion Coefficient (ADC) maps, and perfusion metrics, all compiled into a structured report based on PI-RADS guidelines.
QUIBIM Precision Prostate has received several regulatory clearances, including FDA 510(k) clearance in the US, CE mark for the European Union, UKCA mark for the United Kingdom, and approval by the TGA in Australia. It is classified as a Class IIb medical device under MDR in Europe and is ISO/IEC 27001:2022 certified, ensuring data security and compliance with HIPAA and GDPR for data processing and storage.
QP-Prostate does not provide a definitive diagnosis, and its outputs must be reviewed by qualified physicians, who retain responsibility for interpreting the findings alongside other clinical information. The software has limitations, such as not detecting lesions in the seminal vesicles or indicating extra-prostatic extension (EPE) presence, and it may limit lesion detection to a maximum of four per case. It is also not recommended for patients with radical prostatectomy, hip prostheses, significant MRI artifacts, or those who have undergone treatments directly affecting prostatic tissue appearance.
QP-Prostate integrates seamlessly with existing PACS systems and fusion biopsy systems, allowing for an automated workflow. It uses QP-Link® to ensure data security by either pseudonymizing or fully anonymizing patient-identifiable data before it leaves the site, and leverages Azure Cloud for processing, ensuring rapid results without needing local computational resources.
Clinical validation studies have shown QP-Prostate to increase radiologist sensitivity by up to 10%, leading to prostate cancer detection rates approaching 90% for expert readers. The AI algorithms are trained using biopsy outcomes as ground truth, which is an industry-first for enhanced diagnostic accuracy and specificity. It aims to overcome limitations of traditional multiparametric MRI, such as long examination times, demanding interpretation, and high inter-reader variability.

Compare QUIBIM Precision Prostate (qp-Prostate)

VS
Quantib Prostate vs QUIBIM Precision Prostate (qp-Prostate)
Oncology AI Direct · 92/100
Both Quantib Prostate and QUIBIM Precision Prostate are FDA-cleared AI solutions designed to enhance prostate MRI interpretation through automated segmentation and PI-RADS compliant reporting. While Quantib Prostate offers…
VS
QP-Prostate® CAD vs QUIBIM Precision Prostate (qp-Prostate)
Oncology AI Direct · 95/100
These two tools are highly comparable, appearing to be different iterations or deployment options of the same core product from Quibim S.L. Both are FDA-cleared AI solutions for…
VS
QUIBIM Precision Prostate (qp-Prostate) vs ProstatID
Oncology AI Direct · 95/100
QUIBIM Precision Prostate and ProstatID are direct competitors, both offering FDA-cleared AI solutions for enhancing prostate MRI interpretation and aiding in cancer detection and diagnosis. While QUIBIM details…

Related Tools

SOPHiA DDM
SOPHiA GENETICS
Oncology AI
SOPHiA DDM™ is an AI-driven and cloud-powered platform that helps clinicians generate real-time, actionable insights for patients with cancer and rare disorders by analyzing complex genomic, radiomic, and multimodal data.
Paid
CerviCARE AI
NTL Healthcare
OB/GYN AI
CerviCARE AI is an AI-powered cervical cancer screening system that analyzes smartphone images of the cervix to predict findings, aiming for early detection.
Lumonus AI
Lumonus
Clinical Decision Support & Reference
Lumonus AI is an AI-powered software that assists healthcare providers with prescriptions, dosing, and treatment for cancer patients, with a module (Sigma) that suggests treatment protocols based on prior plans for similar patients.
DeepBio DeepDx® Prostate
DeepBio
Oncology AI
DeepDx® Prostate leverages deep learning to standardize prostate cancer diagnostics by detecting abnormalities in digital slides with high precision, providing automated Gleason grading, tumor quantification, and tumor length measurements.
AIRA Matrix AI Solutions
AIRA Matrix
Lab & Diagnostics
AIRA Matrix offers AI solutions to improve efficiency and diagnostic accuracy in pathology lab workflows, primarily for prostate and breast cancer, with services like DPaaS and predictive toxicology.
Surgical Reality Viewer
Surgical Reality
Oncology AI
Surgical Reality offers CE- and FDA-certified AI-powered 3D medical imaging and surgical planning software that transforms CT scans into patient-specific 3D models for thoracic surgery, enhancing precision in complex lung procedures.

See all Oncology AI tools →

More from Quibim S.L.

QP-Brain®
Quibim S.L.
Neurology AI
QP-Brain® is an AI-powered medical imaging software by Quibim S.L. that provides quantitative analysis of brain MRI scans for early detection and monitoring of neurodegenerative diseases like Alzheimer's and MS. It automates the quantification of brain structures and white matter hyperintensities, integrating directly with PACS for efficient radiological reporting.
Contact vendor
QP-Prostate® CAD
Quibim S.L.
Oncology AI
QP-Prostate® CAD by Quibim S.L. is an FDA-cleared AI-powered software for the detection and diagnosis of clinically significant prostate cancer using MRI, enhancing diagnostic accuracy and streamlining radiology workflows.
Contact for pricing

View company profile →

Suggest an Edit → | Report an issue | Last Verified: 2026-04-19 | First Added: 2026-04-19

Investors who backed QUIBIM Precision Prostate (qp-Prostate)

Funded through the company that built this tool.

Atria Ventures
VC AI T1
San Francisco, United States
$250k-$1M
Atria Ventures is a solo-GP firm built around a single conviction: the next decade of healthcare and life sciences will be defined…
AI/ML in Healthcare Biotech
AI Tool Finder
AI-powered search. Results may not be comprehensive.